Generic Medicine Info
Indications and Dosage
Seasonal allergic rhinitis
Adult: 120 mg daily (in 1 or 2 divided doses) or 180 mg once daily.
Child: 2-11 years 30 mg bid; ≥12 years Same as adult dose.

Chronic idiopathic urticaria
Adult: 180 mg once daily.
Child: 6 months to <2 years 15 mg bid; 2-11 years 30 mg bid; ≥12 years Same as adult dose.
Renal Impairment
Seasonal allergic rhinitis: Child: 2-11 years Initially, 30 mg once daily; ≥12 years Initially, 60 mg once daily. Adult: Initially, 60 mg once daily.
Chronic idiopathic urticaria: Child: 6 months to <2 years Initially, 15 mg once daily; 2-11 years Initially, 30 mg once daily; ≥12 years Initially, 60 mg once daily. Adult: Initially, 60 mg once daily.
Should be taken on an empty stomach. Do not take w/ fruit juice.
Special Precautions
Patient with current or history of CV disease. Renal and hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Cardiac disorders: Palpitations, tachycardia.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, dyspepsia.
General disorders and administration site conditions: Fatigue.
Immune system disorders: Hypersensitivity reactions (e.g. angioedema, chest tightness, flushing).
Nervous system disorders: Headache, drowsiness, dizziness.
Psychiatric disorders: Insomnia, nervousness, sleep disorders or nightmares.
Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus.
Symptoms: Dizziness, drowsiness, fatigue and dry mouth. Management: Symptomatic and supportive treatment.
Drug Interactions
Increased plasma concentrations with erythromycin and ketoconazole. Reduced bioavailability and absorption with antacids containing Al and Mg.
Food Interaction
Reduced bioavailability with fruit juices, including grapefruit juice.
Lab Interference
May suppress the wheal and flare reactions to skin test antigens.
Description: Fexofenadine is a non-sedating antihistamine and an active metabolite of terfenadine. It competes with histamine for H1-receptor on effector cells in the blood vessels, gastrointestinal tract and respiratory tract.
Onset: 2 hours.
Duration: 24 hours.
Absorption: Rapidly absorbed from the gastrointestinal tract. Bioavailability: Approx 33%. Time to peak plasma concentration: 2 hours (orally disintegrating tab); approx 2.6 hours (conventional tab); approx 1 hour (susp).
Distribution: Plasma protein binding: 60-70% primarily to albumin and α1-acid glycoprotein.
Metabolism: Undergoes minimal metabolism in the liver (approx 5%) to methylester metabolite.
Excretion: Mainly via faeces (80%); via urine (12%, as unchanged drug). Elimination half-life: 14.4 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Fexofenadine, CID=3348, https://pubchem.ncbi.nlm.nih.gov/compound/Fexofenadine (accessed on Jan. 20, 2020)

Store between 20-25°C.
MIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AX26 - fexofenadine ; Belongs to the class of other antihistamines for systemic use.
Anon. Fexofenadine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/03/2017.

Buckingham R (ed). Fexofenadine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/03/2017 .

Children’s Allergy Suspension (Actavis Pharma). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 03/03/2017.

Joint Formulary Committee. Fexofenadine Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/03/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Fexofenadine Hydrochloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 03/03/2017.

Telfast Oral Suspension (Sanofi-Aventis Farmaceutica Ltda.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my/. Accessed 14/03/2019.

Disclaimer: This information is independently developed by MIMS based on Fexofenadine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
  • Fexovid
  • Telfast Oral Suspension
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in